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Summary
Objectives: Currently three tests are approved for the estimation of neutralizing antibodies after
rabies vaccination: the mouse neutralization test (MNT), the rapid fluorescent focus inhibition
test (RFFIT), and the fluorescent antibody virus neutralization (FAVN) test. Performance of these
tests requires a lot of expertise and is generally carried out in reference laboratories and, hence,
they are not available tomany people. The aim of the present studywas to develop and evaluate a
competitive ELISA (C-ELISA) for estimation of neutralizing antibodies in order to make this testing
more widely available.
Methods: The C-ELISA was designed based on competition between a murine neutralizing
monoclonal antibody (Mab) and the antibodies in serum of vaccinated people. The test was
initially standardized using known negative and known positive serum samples for determining
the optimal dilution of the Mab as well as the cut-off value (%) for ascertaining the level of
inhibition. Nine hundred and ninety serum samples were tested from 250 people who had been
administered purified chick embryo cell vaccine (PCECV). Serum samples were collected on days
0, 14, 30 and 90 post-vaccination, and were tested by C-ELISA.
Results: All the serum samples that were positive by RFFIT were also positive by C-ELISA. The
titers obtained with C-ELISA were marginally higher than the RFFIT titers, but a significant
correlation was noted between the two tests (r = 0.897). None of the negative controls were
detected to be positive for rabies antibodies by either of these tests. Therefore the C-ELISA was
found to be 100% specific and sensitive in comparison to RFFIT. Further, the initial rise and fall of
antibody titers on different days post-vaccination was comparable for both tests.* Corresponding author. Fax: +91 80 26564830.
E-mail addresses: snmadhu@nimhans.kar.nic.in, mshampur@hotmail.com (S.N. Madhusudana).
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Conclusions: The C-ELISA described herein can be used to quantify rabies neutralizing antibody
levels after vaccination. This test is simple and can be conveniently used under field conditions for
monitoring seroconversion after post-exposure rabies vaccination. Moreover it does not require
handling of infectious virus by the end user.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Rabies is a fatal zoonotic viral infection of the central nervous
system that is transmitted by the bite of an infected animal.
According to a World Health Organization (WHO) estimate,
50 000 human deaths due to rabies are reported worldwide
every year, the majority of them being in the developing
countries of Asia and Africa.1 Amongst these 50 000 cases,
India alone accounts for 20 000.2 More than 95% of cases of
human rabies in India are due to dog bites. The disease is also
re-emerging as an important public health problem in North
America where several cases of human rabies have occurred
due to exposure to bats.3 Recently some cases of human rabies
due to exposure to bats have also been reported from Brazil.4
In India more than 4 million people receive post-exposure
vaccination annually. In January 2005, use of the nerve
tissue vaccine was discontinued and presently the vaccines
used are purified chick embryo cell rabies vaccine (PCECV),
purified vero cell rabies vaccine (PVRV) and purified duck
embryo vaccine (PDEV). All these vaccines protect the indi-
vidual by producing neutralizing antibodies to rabies glyco-
protein (G). WHO has recommended a titer of 0.5 IU/ml of
serum as an accepted level of seroconversion.5
Monitoring antibody titers are required in certain circum-
stances, i.e., elderly people and themalnourished and immu-
nocompromised, and also when clinical trials are conducted
for new vaccines or new vaccination schedules. Currently
three tests are approved by WHO for determining the levels
of rabies neutralizing antibodies: the mouse neutralization
test (MNT),6 the rapid fluorescent focus inhibition test
(RFFIT)7 and the fluorescent antibody virus neutralization
(FAVN) test.8 These tests are time consuming, require exper-
tise, are expensive and are generally carried out in reference
laboratories and, hence, are not widely available. Therefore
there is a need to develop and standardize simple techniques
such as ELISA for the measurement of antibodies. ELISA tests
developed earlier by Perrin et al. do not actually measure
neutralizing antibodies.9 However, it is possible to measure
the levels of neutralizing antibodies by using the principle of
competitive ELISA, where the antibodies in the test serum
are allowed to compete with biotin/enzyme-labeled neutra-
lizing monoclonal antibodies with a known titer. Based on this
principle Sugiyama et al. have developed a competitive ELISA
(C-ELISA) as a simple, rapid and inexpensive alternative to
the virus neutralization test and have used this test to
determine the overall immune status of rabies-vaccinated
domestic dogs in Japan.10 However, this principle has not
been used widely for measuring humoral immunity in people
receiving post-exposure rabies vaccination. In this study we
have developed a C-ELISA for estimating the neutralizing
antibody titer in vaccinated people and evaluated our results
with RFFIT, which is an approved test for estimating rabies-
neutralizing antibodies.Materials and methods
Serum samples
In this assay, serial serum samples (n = 990) obtained from
250 individuals who had received a course of post-exposure
vaccination with PCECV were evaluated. Their antibody
titers on day 0 (n = 250), day 14 (n = 250), day 30 (n = 250)
and day 90 (n = 240), were evaluated. These samples were
obtained from the antirabic treatment center, Kempegowda
Institute of Medical Sciences (KIMS), Bangalore. Negative
controls consisted of 50 serum samples obtained from age
and gender-matched people who had not received any rabies
vaccine. In addition, a panel of 50 positive serum samples,
previously tested positive by RFFIT, was used to validate the
results of the C-ELISA.
Monoclonal antibodies (Mabs)
In a recently completed study, we produced and character-
ized Mabs to rabies virus (CVS 11 strain) in our laboratory by
using established procedures.11 We were able to generate 50
hybridomas to G protein of which 11 Mabs showed a high virus
neutralizing titer for CVS in RFFIT. We chose one of these
Mabs (2C5E8) in designing the C-ELISA. This Mab had a
neutralizing titer of 1:10 000 000 and belonged to isotype
of IgG, subtype of IgG2a. The Mab recognized a conforma-
tional epitope as revealed by a native polyacrylamide gel
electrophoresis. This Mab was biotinylated using an estab-
lished procedure described earlier.12 The optimal dilution of
the Mab to be used in the competition assay as well as the
percentage inhibition to be used as a cut-off value was
determined by using a panel of known high positive
(n = 50), low positive (n = 50) and negative sera (n = 50).
Preparation of antigen for C-ELISA
The CVS strain of rabies virus was grown in BHK-21 cells. Cell-
culture supernatants containing high titers (107 FFD50 (50%
fluorescent focus forming dose)) of rabies virus were clarified
by low-speed centrifugation at 500 g for 30 min, to remove
cellular debris. After clarification and inactivation with beta-
propiolactone (BPL, 1:4000) the virus was partially purified
by ultracentrifugation at 70 000 g and 4 8C for 2 h using an
ultracentrifuge (Sorvall Discovery, 100S). The pelleted virus
was resuspended in phosphate-buffered saline (PBS) to a final
volume of 1/100 of the original and stored at 70 8C until
required.
Rapid fluorescent focus inhibition test (RFFIT)
This was performed as per the WHO advocated procedure
with some modifications. Instead of tissue culture chambers
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Figure 2 Antibody titers (GMT) obtained with C-ELISA (^) and
RFFIT (&) on different days post-vaccination.
Figure 1 Standardization of C-ELISA. Different dilutions of Mab
were tested with a 1:100 dilution of high-titered positive sera
(n = 50 (~)), low-titered positive sera (n = 50 (&)) and known
negative sera (n = 50 (^)). The mean percentage inhibition
obtained with each set of serum against different dilutions of
Mab is depicted. The horizontal line represents the percentage
cut-off value, which is 30%.we used 96-well flat-bottomed tissue culture plates and the
cell line used was BHK-21 (CL 13). The virus used was the CVS
strain adapted to grow in BHK-21 cells and the dose used was
100 FFD50. The highest dilution of serum showing 50% inhibi-
tion of fluorescent foci in the infected cells was taken as the
titer of the serum, whichwas converted to international units
(IU/ml) by comparison to an in-house reference sera cali-
brated against the 2nd international reference serum with a
unitage of 30 IU/ml (obtained from the National Institute of
Biologicals, UK).
C-ELISA
The polystyrene wells of ELISA strips (Nunc, Denmark) were
coated with 1 mg of antigen in 0.05 M carbonate buffer pH 9.6
(0.5% of sodium carbonate and 0.4% of sodium bicarbonate),
at 4 8C overnight. The plates were then washed three times
with PBS containing 0.5% Tween 20 (PBST) to remove unbound
antigen. Subsequently they were treated with 5% skimmed
milk powder in PBS (150 ml/ well) at 37 8C for 2 h to block the
nonspecific reactions. Serial two-fold dilutions of sera
(100 ml) were placed in duplicate in the antigen-coated wells
and then incubated at 37 8C for 30 min. After washing the
plates three times with PBST an appropriate dilution (1:800)
of biotinylated anti-G Mab (100 ml) was added and further
incubated for 1 h. In order to determine the actual OD value
obtained in the absence of competition, five wells received
only 100 ml of PBS in lieu of patient’s serum sample followed
by the same dilution of biotinylated Mab. After five washes,
streptavidin-peroxidase (Bangalore Genei, 1:5000) was
added to each well and incubated as above. After a final
five washes, the substrate OPD (orthophenylenediamine)
solution containing 0.01% H2O2 was added and plates incu-
bated in the dark for 30 min at room temperature. The
development of color was stopped with 4 N H2SO4. The
resulting optical density at 490 nm (OD490) was measured
on an ELISA reader (Lab systems, India). The percentage
inhibition was calculated using the formula [1 — (ODser/
ODMab)]  100, where ODser is the mean of OD of serum + Mab
wells and ODMab is the mean of OD of wells containing Mab
alone. The serum titer was defined as the reciprocal of
the highest dilution that showed 30% or more of inhibition
of OD value of the competing Mab. The titers were converted
to IU/ml by comparison to the titers observed with an in-
house reference serum (as described earlier).
Statistical analysis
The results obtained with the two tests were analyzed by
Pearson’s product movement correlation test and the r-value
determined.
Results
Standardization of C-ELISA
Initially, the C-ELISA was standardized for optimal conditions
using a 1:100 dilution of negative, high positive and low
positive sera, based on the results of RFFIT done earlier.
The results are shown in Figure 1. The optimal dilution of the
biotinylated neutralizing Mab to be used in the C-ELISA wasdetermined to be 1:800. This was arrived at as more than 80%
inhibition was observed with strong positive sera and less
than 10% inhibition with known negative sera. The cut-off
percentage inhibition was taken as 30% based on the inhibi-
tion values obtained with low positive sera.
Comparison of RFFIT and C-ELISA
To evaluate the C-ELISA, 990 serum samples obtained from
individuals who had received a post-exposure immunization
with PCECV were assayed in both the RFFIT and the C-ELISA.
The serum samples were tested in duplicate at different
dilutions (1:500 to 1:8000) and the geometric mean titer
(GMT) of the reciprocal of the highest dilution showing 30%
inhibition was calculated. The antibody titers obtained by
C-ELISA as compared to those obtained by RFFITare shown in
Figure 2 and Table 1. The distribution of all the samples
tested (both positive and negative) and their percentage
inhibition of OD values are shown in Figure 3. Though the
antibody titers obtained by C-ELISA were marginally higher
than those obtained by RFFIT, there was a good correlation
between the two (Figure 4; r = 0.897). It can be also observed
that there is a good correlation between the two tests on the
different days following vaccination (Figure 2). The antibody
titers reached a peak in the C-ELISA and the RFFIT on day 30
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Figure 4 Scatter plot showing correlation between GMT of C-
ELISA and RFFIT determined using SPSS software (Statistical
Package for Social Sciences). The r-value was found to be 0.897.
Figure 3 Distribution of percentage inhibition (PI) values for
740 positive serum samples and 250 negative serum samples
obtained by the C-ELISA. The threshold cut-off value of a PI of 30
was determined on the basis of OD values of low positive serum
samples (mean PI + 3 standard deviations).post-vaccination. The two assays gave similar patterns of
initial rise by day 14 and subsequent fall by day 90. As all the
samples tested positive by C-ELISA were also positive by
RFFIT, the specificity/sensitivity index was found to be 1.
Discussion
Rabies is a fatal disease once symptoms develop. However it
is a preventable disease if state of the art modern prophy-
lactic techniques are instituted soon after exposure. Vacci-
nation with a potent rabies vaccine plays a crucial role. The
presence of adequate titers of neutralizing antibodies in
serum indicates protective immunity.
The RFFIT, FAVN test and MNT are neutralization-based
tests and have been used for detecting and measuring neu-
tralizing antibodies to rabies virus. However, these tests are
tedious and require use of live virus and animal/cell culture,
making them unsuitable for determining the protective sta-
tus following post-exposure prophylaxis under field condi-
tions. Of these, the more recently developed neutralization
test —FAVN — is relatively economical but still has the same
limitations.13
To overcome this disadvantage, ELISAs have been devel-
oped for detecting antibodies to rabies virus.7,14—16 The
conventional ELISA developed earlier does not measure the
neutralizing antibodies alone and antibodies to other epi-
topes are also measured. Thus, results of ELISA may not
actually indicate the protective status of the vaccinated
individual. This problem was overcome in the present study
by developing a competitive ELISA using a neutralizing G
Mab (2C5E8) that recognized a conformational epitope on
the rabies G protein, allowing the serum samples to com-
pete with this Mab for the G antigen of the concentratedTable 1 Comparison of GMT of neutralizing antibody (IU/ml) obt
Day of sampling RFFIT titer (GMT) I
Day 0 (n = 250) ND
Day 14 (n = 250) 7.5
Day 30 (n = 250) 15
Day 90 (n = 240) 4.84
GMT, geometric mean titer; RFFIT, rapid fluorescent focus inhibition tvirus coated onto solid phase. In a direct C-ELISA for
measuring antibody levels, a known amount of specific
indicator antibody (Mabs conjugated with an enzyme) is
mixed with the serum under test and allowed to compete
for a limited amount of antigen bound to a solid matrix.
When the enzyme substrate is added to the system (in the
presence of a chromogen), a decrease in color intensity
indicates competition and therefore the presence of anti-
body in the test serum. The decrease in color intensity is
proportional to the level of antibody unless there is com-
plete inhibition of the labeled antibody. C-ELISA has been
used earlier for measuring the immune status of animals to
diseases such as rinderpest virus,17 morbillivirus18 and blue-
tongue virus,19 and for ascertaining immune status in
human leishmaniasis.20
The initial standardization of the assay was done using
checkerboard titration of neutralizing Mab with known posi-
tive and negative serum samples and the cut-off value
(percentage inhibition of OD value) was determined. In this
study, 990 serum samples obtained from patients who were
immunized with rabies vaccine (PCECV) were tested. Though
the titers obtained with C-ELISA were marginally higher than
RFFIT titers (Figure 2) there was an excellent correlation
between the two tests (r = 0.897). In addition, the antibody
titers observed on different days post-vaccination showed an
identical pattern of initial rise and subsequent fall. The test is
both specific and sensitive and takes about 4 hours to com-
plete. The actual test procedure is not complicated as
compared to conventional ELISA. Because of the use of Mabsained with RFFIT and C-ELISA
U/ml C-ELISA titer (GMT) IU/ml
ND
11.25
22.5
7.5
est; ND, not detected.
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highly purified G protein for initial capturing of neutralizing
antibodies. Concentrated, inactivated and partially purified
virus can be used. Results can be obtained within 4 hours
compared to RFFIT, which takes 48—72 hours, and MNT, which
takes 14 days.
The earlier study of Sugiyama et al. evaluated C-ELISA
using several Mabs against G protein but found a poor corre-
lation with the neutralization test when they tested immu-
nized dog sera.10 This finding is in contrast to our results in
the current study, where we have found a very good correla-
tion between the tests when human samples were tested.
However, they found a good correlation (r = 0.9) when Mabs
against N protein were used in the C-ELISA. It is probable that
because of the low antigenicity of the veterinary vaccine and
administration of only one or two doses of vaccine, dog sera
may not have sufficient levels of antibodies reactive to G
protein. This is not the case with human sera as all our
subjects had received five doses of highly potent rabies
vaccine.
One limitation of this assay is that the titers obtained are
not expressed as conventional IU/ml as is done with MNT,
RFFIT or the FAVN test. However, it may be possible to
include the presently used international standard of rabies
immune globulin (RIG) or more practically an in-house refer-
ence serum (calibrated against the international standard) in
this C-ELISA and titers can be converted to IU/ml. However,
more studies are required to address this issue.
In summary, the C-ELISA is a convenient and practical
assay for detecting and measuring neutralizing antibodies to
rabies virus. The reagents necessary for the test can be
prepared in a reference laboratory and the actual test can
be performed in peripheral laboratories. Its development
provides a rapid, simple, safe, and economical means for
large serological surveys, both in man and animals, which is
essential for determining the efficacy of vaccination after
pre- or post-exposure therapy.
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